Nama's AI scorecard currently rates AnaptysBio Hold (5.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ANAB's P/E ratio?

AnaptysBio trades at a trailing price-to-earnings ratio of 8.2.

When does ANAB report earnings?

AnaptysBio's next scheduled report is on Nov 11, 2026. Analysts expect EPS of $0.53.

What is the ANAB price target?

The median analyst price target from 8 analysts is $79.50, with a range of $60.00 – $140.00.

Is ANAB Shariah compliant?

Nama's AAOIFI-style screen reads AnaptysBio as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

AnaptysBio (ANAB)

Healthcare · Biotechnology · NASDAQ

AnaptysBio (ANAB) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.39B, a trailing price-to-earnings ratio of 8.2 and a free-cash-flow yield of 1.5%. Over the most recent reported fiscal year, revenue grew 157.0%. Nama's AI scorecard rates it Hold, 5.7 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.7/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +19.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-36.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.39B
Trailing P/E	8.2
Price / book	105.6
Price / sales	13.1
FCF yield	1.5%
Dividend yield	—
Gross margin	105.0%
Operating margin	53.4%
Net margin	247.0%
Revenue growth (YoY)	+157.0%
Revenue growth (3-yr annual)	+183.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ANAB earnings

Next report: Nov 11, 2026 (Q1 2027, EPS estimate $0.53). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q4 2026	Sep 21, 2026	$4.93	$0.14	+3421.4%	—
Q2 2026	Mar 3, 2026	$1.58	$0.93	+69.9%	$108.25M
Q1 2026	Nov 4, 2025	$0.52	-$1.25	+141.6%	$76.32M
Q4 2025	Aug 6, 2025	-$1.34	-$1.58	+15.2%	$22.26M

ANAB analyst price target

Median target $79.50 from 8 analysts, ranging $60.00 – $140.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ANAB data on Nama Insights →

ANAB FAQ

Is ANAB a buy?: Nama's AI scorecard currently rates AnaptysBio Hold (5.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ANAB's P/E ratio?: AnaptysBio trades at a trailing price-to-earnings ratio of 8.2.
When does ANAB report earnings?: AnaptysBio's next scheduled report is on Nov 11, 2026. Analysts expect EPS of $0.53.
What is the ANAB price target?: The median analyst price target from 8 analysts is $79.50, with a range of $60.00 – $140.00.
Is ANAB Shariah compliant?: Nama's AAOIFI-style screen reads AnaptysBio as Not Shariah Compliant. At least one of the three ratios or the industry test failed.